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Secondary hyperparathyroidism (SHPT) affects a significant
number of hemodialysis patients, and metabolic disturbances
associated with it may contribute to their high mortality rate.
As patients with lower serum calcium, phosphorus, and
parathyroid hormone are reported to have improved
survival, we tested whether prescription of the calcimimetic
cinacalcet to hemodialysis patients with SHPT improved their
survival. We prospectively collected data on hemodialysis
patients from a large provider beginning in 2004, a time
coincident with the commercial availability of cinacalcet
hydrochloride. This information was merged with data in the
United States Renal Data System to determine all-cause and
cardiovascular mortality. Patients included in the study
received intravenous (i.v.) vitamin D therapy (a surrogate for
the diagnosis of SHPT). Of 19,186 patients, 5976 received
cinacalcet and all were followed from November 2004 for up
to 26 months. Unadjusted and adjusted time-dependent Cox
proportional hazards modeling found that all-cause and
cardiovascular mortality rates were significantly lower for
those treated with cinacalcet than for those without
calcimimetic. Hence, this observational study found a
significant survival benefit associated with cinacalcet
prescription in patients receiving i.v. vitamin D. Definitive
proof, however, of a survival advantage awaits the
performance of randomized clinical trials.
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Despite recent modest improvements in adjusted mortality
rates among hemodialysis patients, mortality rates remain
above 225 per 1000 patient-years, nearly six times the rates in
the general age-matched population.1 Overall 5-year survival
of hemodialysis patients remains only 31% and the mortality
rate for patients on dialysis for longer than 5 years is above
250 per 1000 patient-years.1 In the last decade, considerable
emphasis has been placed on the role of abnormalities in
mineral metabolism (elevated levels of calcium, phosphorus,
and parathyroid hormone (PTH)) in this high rate of
mortality.2 Secondary hyperparathyroidism (SHPT) is pre-
sent in a substantial percentage of hemodialysis patients and
prevalence increases with increasing dialysis duration. For
much of the past two decades, the primary SHPT treatments
have been phosphate binders to control serum phosphorus,
and intravenous (i.v.) vitamin D to suppress PTH. As i.v.
vitamin D commonly increases serum calcium and phos-
phorus, efforts to control PTH often resulted in elevated
serum calcium and phosphorus values.
Elevations in serum calcium, phosphorus, and PTH have
all been associated with increased morbidity and mortality in
observational studies.3–6 Observational data suggest that
optimal outcomes are associated with serum calcium values
in the low-normal range of 7.5–9.5 mg/dl and serum
phosphorus values in the range of 3–5 mg/dl.5 Serum PTH
levels associated with optimal outcomes are less well defined
and vary by specific study; however, it is difficult to show an
independent effect of PTH on outcomes until PTH values are
above 600 pg/ml.6
The strength of observational data has led to many
national and international patient care guidelines that
recommend control of serum calcium, phosphorus, and
PTH within specific ranges. The most well recognized of
these sets of guidelines is the US-based National Kidney
Foundation Kidney Disease Outcomes Quality Initiative
(KDOQI). The KDOQI guideline for bone and mineral
disease recommends target calcium of 8.4–9.5 mg/dl, target
phosphorus of 3.5–5.5 mg/dl, and target PTH of 150–300 pg/ml.7
Calcimimetics increase the sensitivity of the calcium-
sensing receptor to extracellular calcium and represent an
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alternative therapy for SHPT. The first calcimimetic,
cinacalcet hydrochloride (Sensipar; Amgen, Thousand Oaks,
CA, USA), was approved for clinical use in April 2004 and
became commercially available in May 2004. Pivotal clinical
trials were conducted in patients with persistent SHPT despite
use of a standard therapy (phosphate binders and vitamin D).
These trials consistently showed that adding cinacalcet reduced
PTH, calcium, and phosphorus levels.8 Extension studies and
post-hoc analyses suggested that adding cinacalcet produced
long-term favorable effects on these biomarkers and that
patients given cinacalcet were more likely to reach target values
than patients given standard therapy.9,10
Compelled by the observations that patients with lower
serum values of calcium, phosphorus, and PTH had
improved survival, we prospectively tested the hypothesis
that prescribing cinacalcet to a large hemodialysis population
with SHPT would be associated with improved survival.
RESULTS
Baseline characteristics
The final study population consisted of 5976 patients with
cinacalcet prescriptions and 13,210 without. Detailed
descriptions of patient characteristics at baseline and at first
cinacalcet prescription are shown in Tables 1 and 2. Patients
with cinacalcet prescriptions were younger with longer
dialysis duration, more likely to be African American, and
less likely to have diabetes. In the baseline period, a higher
percentage of patients with cinacalcet prescriptions had 0
hospital days and a lower percentage had 45 hospital days.
Consistent with these demographic differences suggesting
that patients with cinacalcet prescriptions were generally
healthier, baseline cardiovascular comorbidity was also lower.
Cardiovascular medication use was generally similar between
patients with and without cinacalcet prescriptions; however,
cinacalcet patients were less likely to receive prescriptions
for calcium-containing phosphate binders and more likely to
receive prescriptions for sevelamer. Baseline serum calcium,
phosphorus, and PTH values were higher for cinacalcet than
for non-cinacalcet patients. In particular, proportions of
cinacalcet patients with severe hyperparathyroidism (PTH
4600 pg/ml), hypercalcemia (calcium 410.2 mg/dl), and
hyperphosphatemia (phosphorus 48.0 mg/dl) in the base-
line period were higher than proportions of non-cinacalcet
patients.
Outcomes analyses: mortality
The unadjusted all-cause mortality rate for patients with
cinacalcet prescriptions was significantly lower than for non-
cinacalcet patients (17.6 vs 23.0 deaths per 100 patient-years,
respectively, hazard ratio (HR) 0.73, 95% confidence interval
(CI) 0.68–0.78, Po0.001; Table 3). Fully adjusted models
showed an almost identical HR of 0.74 (95% CI 0.67–0.83),
suggesting that demographic characteristics favoring cina-
calcet patients were balanced by laboratory characteristics
favoring non-cinacalcet patients (Table 4). Unadjusted
cardiovascular mortality rates were 8.1 deaths per 100
patient-years for cinacalcet patients and 10.0 for non-
cinacalcet patients. Models adjusted for all variables showed
an HR of 0.76 (95% CI 0.66–0.86, Po0.001) for cardiovas-
cular mortality (Table 5).
Concomitant medication use (cardiovascular, lipid low-
ering) and phosphate binder use were investigated as
covariates. However, there was no statistically significant
association between use of these medications during the
baseline period and mortality. Removing these medications
from the model did not affect the parameter estimate for
all-cause mortality or cardiovascular-specific mortality.
Stratified analysis
Although we detected no interactions between treatment and
any factor of interest (age, sex, race, dialysis duration,
diabetes, access type, body mass index (BMI), phosphorus,
and PTH), and despite adjustment for multiple baseline
covariates, slight differences in treatment effect between
strata of covariates could occur. Thus, fully adjusted time-
dependent stratified analyses were conducted for all-cause
mortality. The upper end of the 95% CI was o1.0 in 46 of
the 59 strata presented (Figure 1). Stratification by severity of
SHPT revealed no survival benefit for patients with PTH
o150 pg/ml (HR 0.97, CI 0.74–1.26) and the largest survival
benefit (HR 0.66, CI 0.53–0.83) for patients with the most
severe disease (PTH 4600 pg/ml). We also conducted
stratified analyses for associations with cardiovascular
mortality. Trends were similar, except that CI were even
wider and overlapped 1.0 more often, reflecting smaller
numbers of events.
Sensitivity analyses using dialysis duration and propensity
matched cohorts revealed a HR of 0.81 (CI 0.75–0.88).
DISCUSSION
This prospectively designed observational study, initiated in
2004, shows a significant survival benefit associated with
prescribing cinacalcet for hemodialysis patients with evidence
of SHPT and receiving i.v. vitamin D. This survival benefit
was maintained after adjustment for baseline and time-
dependent characteristics. Sensitivity analyses designed to
address the difference in dialysis duration between groups
(and possible lead-time bias) modified the HR towards 1;
however, significant survival benefit was maintained. In
stratified analysis, the upper end of the 95% CI was o1 in
most strata, supporting a consistent benefit among sub-
groups. Improved survival was also shown for cardio-
vascular mortality, consistent with the hypothesis that
intervention in mineral metabolism is directly related to
cardiovascular health in hemodialysis patients. That stratified
analyses failed to show a survival effect in patients with PTH
o150 pg/ml and the strongest effect was observed in patients
with the most severe SHPT (PTH 4600 pg/ml) strongly
support this hypothesis.
Because cinacalcet use has been shown to result in
decrements in serum levels of calcium, phosphorus, and
PTH, it is tempting to speculate that these reductions may be
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the proximate cause of a survival benefit. Indeed, the strength
of the observational data suggesting that high levels of these
minerals are associated with mortality led to the development
of national and international guidelines that adopt narrow
target values.11 The KDOQI guidelines for bone and mineral
disease recommend target levels of 8.4–9.5 mg/dl for calcium,
3.5–5.5 mg/dl for phosphorus, and 150–300 pg/ml for PTH.
A recent report using data from a large dialysis provider
(Fresenius Medical Care North America, Waltham, MA,
USA) found that consistent control of mineral metabolism
was associated with improved survival for hemodialysis
patients, and that as patients met increasing numbers of
KDOQI targets, HR of mortality were reduced.12 In addition,
sustaining each target level over time was associated with
improved survival. The authors estimated that maintaining
KDOQI targets for calcium, phosphorus, and PTH could
reduce mortality by as much as 20%. Using data from DaVita
(Denver, CO, USA), we recently reported that serum calcium,
phosphorus, and PTH were significantly reduced for patients
given cinacalcet prescriptions from mid 2004 to 2006, and
these patients were more likely to reach KDOQI target values
and less likely to experience biochemical adverse events.13
Table 1 | Patient demographic and health information at baseline (1 November 2004) and at first cinacalcet use
Cinacalcet patientsa
All patients,a 1 November 1 November At first cinacalcet useb Non-cinacalcet patients,a 1 November
Characteristics n Percent n Percent n Percent n Percent
Mean age (year) 62.9 58.3 59.2 65.0
Age groups, % 19,186 5976 5976 13,210
0–44 2418 12.6 1119 18.7 1030 17.2 1299 9.8
45–64 6976 36.4 2602 43.5 2578 43.1 4374 33.1
65–74 5108 26.6 1405 23.5 1424 23.8 3703 28.0
X75 4684 24.4 850 14.2 944 15.8 3834 29.0
Mean dialysis duration (year) 3.8 4.4 5.3 3.5
Dialysis duration, % 19,179 5975 5976 13,204
o1 3189 16.6 704 11.8 133 2.2 2485 18.8
1–3 6485 33.8 1755 29.4 1521 25.5 4730 35.8
3–5 4719 24.6 1599 26.8 1769 29.6 3120 23.6
45 years 4786 25.0 1917 32.1 2553 42.7 2869 21.7
Mean body mass index (kg/m2) 18,861 26.9 5861 27.7 5866 27.6 12,820 26.5
Body mass index, %
0o18.5 906 4.9 216 3.7 215 3.7 690 5.4
X18.5 to o25.0 7569 40.5 2168 37.0 2210 37.7 5401 42.1
X25.0 to o30.0 5439 29.1 1712 29.2 1723 29.4 3727 29.1
X30.0 to o35.0 2722 14.6 935 16.0 910 15.5 1787 14.0
X35.0 to o40.0 1220 6.5 496 8.5 480 8.2 724 5.7
X40.0 825 4.4 334 5.7 328 5.6 491 3.8
Sex
Men 10,310 53.7 3096 51.8 3096 51.8 7214 54.6
Women 8876 46.3 2880 48.2 2880 48.2 5996 45.4
Race
African American 7821 40.8 3018 50.5 3018 50.5 4803 36.4
White 6309 32.9 1592 26.6 1592 26.6 4717 35.7
Other 5056 26.4 1366 22.9 1366 22.9 3690 27.9
Primary cause of renal failure
Diabetes 8760 45.7 2401 40.2 2401 40.2 6359 48.1
Hypertension 5853 30.5 1957 32.8 1957 32.8 3896 29.5
Glomerulonephritis 1851 9.7 730 12.2 730 12.2 1121 8.5
Other 2722 14.2 888 14.9 888 14.9 1834 13.9
Hospital days
0 10,566 55.1 3541 59.3 3579 59.9 7025 53.2
1–3 2307 12.0 744 12.5 773 12.9 1563 11.8
4–5 1181 6.2 353 5.9 360 6.0 828 6.3
45 5132 26.8 1338 22.4 1264 21.2 3794 28.7
aDemographic information defined on 1 November 2004; baseline hospital days determined from 1 May to 31 October 2004.
bCharacteristics collected immediately before first cinacalcet prescription or, for hospital days, in the 6 months before first cinacalcet prescription.
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Table 2 | Comorbid conditions, medication use, and laboratory values at baseline (1 November 2004) and at first cinacalcet use
Cinacalcet patientsa
All patients,a 1 November 1 November At first cinacalcet useb Non-cinacalcet patients,a 1 November
Characteristics n Percent n Percent n Percent n Percent
Diabetes 11,672 60.8 3241 54.2 3284 55.0 8431 63.8
CVD
CHF 8886 46.3 2427 40.6 2483 41.5 6459 48.9
ASHD 6866 35.8 1716 28.7 1807 30.2 5150 39.0
PVD 6859 35.8 1783 29.8 1892 31.7 5076 38.4
CVA/TIA 3284 17.1 796 13.3 813 13.6 2488 18.8
Dysrhythmia 4730 24.7 1093 18.3 1234 20.6 3637 27.5
Other CVDc 5879 30.6 1594 26.7 1607 26.9 4285 32.4
Cancer 1579 8.2 424 7.1 420 7.0 1155 8.7
COPD 3118 16.3 795 13.3 873 14.6 2323 17.6
Beta blockersd 10,442 54.4 3370 56.4 3601 60.3 7072 53.5
Calcium channel blockerse
Dihydropyridine 9012 47.0 2997 50.2 3023 50.6 6015 45.5
Nondihydropyridine 1554 8.1 519 8.7 512 8.6 1035 7.8
Statinsf 6036 31.5 1774 29.7 1900 31.8 4262 32.3
ACEIs/ARBsg 11,030 57.5 3590 60.1 3628 60.7 7440 56.3
Phosphate binders
Calcium-based 9980 52.0 2850 47.7 2511 42.0 7130 54.0
Lanthanum — 0.0 — 0.0 939 15.7 0 0.0
Sevelamer 10,134 52.8 4004 67.0 4444 74.4 6130 46.4
Albumin, g/dl, mean (s.d.) 18,985 3.9 (0.4) 5935 3.9 (0.4) 5904 3.9 (0.4) 13,050 3.8 (0.4)
Albumin, %
o3.6 3807 20.1 830 14.0 942 16.0 2977 22.8
X3.6 to o4.0 6815 35.9 2060 34.7 2074 35.1 4755 36.4
X4.0 8363 44.1 3045 51.3 2888 48.9 5318 40.8
Corrected calcium, mg/dl, mean (s.d.) 18,918 9.6 (0.7) 5923 9.8 (0.7) 5895 9.7 (0.7) 12,995 9.5 (0.7)
Corrected calcium, %
o9.0 2586 13.7 527 8.9 781 13.2 2059 15.8
X9.0 to p10.2 13,198 69.8 3898 65.8 3658 62.1 9300 71.6
410.2 3134 16.6 1498 25.3 1456 24.7 1636 12.6
Phosphorus, mg/dl, mean (s.d.) 18,990 5.4 (1.6) 5936 5.7 (1.6) 5906 6.1 (1.7) 13,054 5.2 (1.5)
Phosphorus, %
o3.5 1467 7.7 265 4.5 203 3.4 1202 9.2
X3.5 to o5.0 6595 34.7 1714 28.9 1386 23.5 4881 37.4
X5.0 to o6.0 5118 27.0 1683 28.4 1514 25.6 3435 26.3
X6.0 to o7.0 3073 16.2 1136 19.1 1233 20.9 1937 14.8
X7.0 to o8.0 1527 8.0 623 10.5 797 13.5 904 6.9
X8.0 1210 6.4 515 8.7 773 13.1 695 5.3
Intact PTH, pg/ml, median (IQR) 18,830 251.9 (225.0) 5902 323.1 (317.3) 5890 548.1 (465.5) 12,928 230.8 (186.5)
Intact PTH, %
o150 3696 19.6 730 12.4 219 3.7 2966 22.9
X150 to p300 7844 41.7 2010 34.1 683 11.6 5834 45.1
4300p600 5248 27.9 2005 34.0 2408 40.9 3243 25.1
4600 2042 10.8 1157 19.6 2580 43.8 885 6.8
Hemoglobin, g/dl, mean (s.d.) 18,959 12.4 (1.4) 5929 12.4 (1.3) 5899 12.4 (1.3) 13,030 12.3 (1.4)
Hemoglobin, %
o10 84 4.4 218 3.7 215 3.6 625 4.8
X10 to p12 6566 34.6 1950 32.9 2058 34.9 4616 35.4
Table 2 Continued on the following page
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Table 2 | Continued
Cinacalcet patientsa
All patients,a 1 November 1 November At first cinacalcet useb Non-cinacalcet patients,a 1 November
Characteristics n Percent n Percent n Percent n Percent
412 to p13 5398 31.3 1954 33.0 1919 32.5 3984 30.6
413 5612 29.6 1807 30.5 1707 28.9 3805 29.2
Bicarbonate, mEq/l, mean (s.d.) 18,925 21.2 (4.0) 5922 21.0 (3.9) 5894 23.2 (3.7) 13,003 21.3 (4.0)
Bicarbonate, %
o22 10,204 53.9 3303 55.8 1893 32.1 6901 53.1
X22 to p30 8503 44.9 2555 43.1 3832 65.0 5948 45.7
430 218 1.2 64 1.1 169 2.9 154 1.2
Kt/V UKM, mean (s.d.) 18,832 1.7 (0.3) 5908 1.6 (0.3) 5882 1.6 (0.3) 12,924 1.7 (0.3)
Kt/V UKM, %
o1.2 1032 5.5 308 5.2 312 5.3 724 5.6
X1.2 to p1.4 2264 12.0 721 12.2 716 12.2 1543 11.9
41.4 15,536 82.5 4879 82.6 4854 82.5 10,657 82.5
URR, mean (s.d.) 18,936 73.9 (6.7) 5924 73.8 (6.6) 5889 74.0 (6.6) 13,012 74.0 (6.8)
URR, %
o65 1416 7.5 434 7.3 394 6.7 982 7.5
X65 17,520 92.5 5490 92.7 5495 93.3 12,030 92.5
Abbreviations: ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; ASHD, atherosclerotic heart disease; CHF, congestive heart failure; COPD,
chronic obstructive pulmonary disease; CVA, cerebrovascular accident; CVD, cardiovascular disease; IQR, inter-quartile range; Kt/V, dialysis adequacy; PTH, parathyroid
hormone; PVD, peripheral vascular disease; s.d., standard deviation; TIA, transient ischemic attack; UKM, urea kinetic modeling; URR, urea reduction ratio.
aBaseline comorbidity determined 1 May to 31 October 2004; at least one record of medication prescription in the medication class required in the 3 baseline months
(August–October 2004) to be counted as medication exposure; baseline laboratory data determined 1 August to 31 October 2004, using values closest to 31 October 2004.
bBaseline comorbidity determined in the 6 months before first cinacalcet prescription; at least one record of medication prescription in the medication class required in the 3
months before first cinacalcet prescription to be counted as a medication exposure; baseline laboratory data determined in the 3 months before first cinacalcet prescription.
cIncludes ill-defined complication of heart disease, tachycardia, palpitations, murmurs, acute pericarditis, acute and subacute endocarditis, other diseases of pericardium, and
other diseases of the endocardium.
dAcebutolol, atenolol, betaxolol, bisoprolol, carteolol, carvedilol, esmolol, labetalol, metoprolol, nadolol, penbutolol, pindolol, propranolol, and timolol.
eDihydropyridine-based: amlodipine, bepridil, felodipine, isradipine, nicardipine, nifedipine, and nisoldipine; non-dihydropyridine-based: diltiazem and verapamil.
fAtorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin, and simvastatin.
gACEIs: benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, and trandolapril; ARBs: candesartan, eprosartan, irbesartan, losartan,
telmisartan, and valsartan.
Table 3 | Unadjusted all-cause and cardiovascular mortality
Variable Cinacalcet patients Non-cinacalcet patients P
n 5976 19,174
All-cause mortality
Follow-up
Mean, patient-years 1.1 1.3
Minimum–maximum, years 0.0–2.2 0.0–2.2
Total deaths, n (%) 1148 (19.2) 5882 (30.7)
Mortality incidence rate, per 100 patient-years (95% CI) 17.6 (16.58–18.61) 23.0 (22.38–23.55)
Raw hazard ratioa (95% CI) 0.73 (0.68–0.78) o0.0001
Time to event, monthsb o0.0001
1-year survival (s.e.) 0.85 (0.01) 0.80 (0.00)
2-year survival (s.e.) 0.70 (0.01) 0.63 (0.00)
Cardiovascular mortality
Follow-up
Mean, patient-years 1.1 1.3
Minimum–maximum, years 0.0–2.2 0.0–2.2
Cardiovascular deaths, n (%) 525 (8.8) 2571 (13.4)
Cardiovascular mortality incidence rate, per 100 patient-years (95% CI) 8.1 (7.36–8.73) 10.0 (9.65–10.43)
Raw hazard ratioa (95% CI) 0.78 (0.71–0.86) o0.0001
Time to event, monthsb o0.0001
1-year survival (s.e.) 0.92 (0.00) 0.91 (0.00)
2-year survival (s.e.) 0.85 (0.01) 0.82 (0.00)
Abbreviations: CI, confidence interval; s.e., standard error.
aTime-dependent Cox-proportional hazard regression model.
bLog-rank test.
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Table 4 | Adjusted hazard ratios for all-cause mortalitya
Parameter Parameter estimate s.e. Hazard ratio (95% CI) P
Treatment (referent: non-cinacalcet patients) 0.298 0.054 0.74 (0.67–0.83) o0.0001
Age, year (referent: 18–44)
45–64 0.508 0.106 1.66 (1.35–2.04) o0.0001
65–74 0.847 0.119 2.33 (1.85–2.95) o0.0001
X75 1.147 0.121 3.15 (2.48–3.99) o0.0001
Sex (referent: men) 0.073 0.040 0.93 (0.86–1.01) 0.0669
Race (referent: white)
African American 0.365 0.048 0.69 (0.63–0.76) o0.0001
Other 0.286 0.049 0.75 (0.68–0.83) o0.0001
Dialysis duration, year (referent: 1–3)
o1 0.212 0.061 0.81 (0.72–0.91) 0.0005
3–5 0.119 0.060 1.13 (1.00–1.27) 0.0466
45 0.214 0.074 1.24 (1.07–1.43) 0.0036
BMI, kg/m2 (referent: X18–o25)
o18.5 0.366 0.074 1.44 (1.25–1.67) o0.0001
X25 to o30 0.282 0.043 0.75 (0.69–0.82) o0.0001
X30 to o35 0.416 0.054 0.66 (0.59–0.73) o0.0001
X35 to o40 0.604 0.081 0.55 (0.47–0.64) o0.0001
X40 0.461 0.091 0.63 (0.53–0.75) o0.0001
Primary cause of renal failure (referent: glomerulonephritis)
Diabetes 0.210 0.084 1.23 (1.05–1.46) 0.0124
Hypertension 0.131 0.077 1.14 (0.98–1.33) 0.0873
Other 0.174 0.085 1.19 (1.01–1.41) 0.0402
Hospital days (referent: 0)
1–3 0.038 0.065 1.04 (0.91–1.18) 0.5565
4–5 0.065 0.078 1.07 (0.92–1.24) 0.4058
45 0.126 0.056 1.14 (1.02–1.27) 0.0242
Diabetes (referent: no) 0.187 0.058 1.21 (1.08–1.35) 0.0013
Congestive heart failure (referent: no) 0.250 0.042 1.28 (1.18–1.39) o0.0001
Atherosclerotic heart disease (referent: no) 0.004 0.045 1.00 (0.92–1.10) 0.932
Peripheral vascular disease (referent: no) 0.093 0.040 1.10 (1.01–1.19) 0.0206
CVA/TIA (referent: no) 0.142 0.046 1.15 (1.05–1.26) 0.002
Dysrhythmia (referent: no) 0.169 0.044 1.18 (1.09–1.29) 0.0001
Other CVDb (referent: no) 0.098 0.043 1.10 (1.01–1.20) 0.0245
Cancer (referent: no) 0.163 0.068 1.18 (1.03–1.34) 0.016
GI bleeding (referent: no) 0.086 0.070 1.09 (0.95–1.25) 0.2223
COPD (referent: no) 0.173 0.047 1.19 (1.08, 1.30) 0.0002
Liver disease (referent: no) 0.080 0.116 1.08 (0.86, 1.36) 0.4892
Albumin, g/dl (referent: X4.0)
o3.6 1.014 0.034 2.76 (2.58–2.95) o0.0001
X3.6 to o4.0 0.373 0.030 1.45 (1.37–1.54) o0.0001
Corrected calcium, mg/dl (referent: X9.0–p10.2)
o9.0 0.063 0.082 0.94 (0.80–1.10) 0.4448
410.2 0.127 0.046 1.14 (1.04–1.24) 0.0059
Phosphorus, mg/dl (referent: X3.5–o5.0)
o3.5 0.060 0.116 1.06 (0.85–1.33) 0.6028
X5.0 to o6.0 0.065 0.043 1.07 (0.98–1.16) 0.1279
X6.0 to o7.0 0.141 0.050 1.15 (1.04–1.27) 0.0048
X7.0 to o8.0 0.207 0.069 1.23 (1.07–1.41) 0.0028
X8.0 0.365 0.073 1.44 (1.25–1.66) o0.0001
Intact PTH, pg/ml (referent: 4150–p300)
o150 0.0002 0.065 1.00 (0.88–1.14) 0.9968
4300 to p600 0.025 0.044 1.03 (0.94–1.12) 0.5748
4600 0.171 0.063 1.19 (1.05–1.34) 0.0065
Table 4 Continued on the following page
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However, it is imperative to note that no randomized
clinical trial has shown that reduced serum levels of these
minerals are associated with improved clinical outcome.
Despite the compelling nature of our results, these data most
strongly support the ongoing EVOLVE trial (Evaluation of
cinacalcet HCL therapy to lower cardiovascular events;
clinicaltrials.gov identifier NCT 00345839). Nephrology is
currently mired in an unfortunate situation, in which
observational data are used to generate clinical treatment
guidelines rather than hypotheses to be tested with
randomized controlled clinical trials. Such an approach has
often proved to be erroneous when ultimately tested in
properly conducted clinical trials. Remarkably, some mem-
bers of the community go so far as to suggest that, on the
basis of observational data alone, conducting randomized
controlled trials is precluded on ethical grounds. We must
resist adopting this approach.
As with all observational reports, the current study has
several limitations. Chief among these is the possibility that
residual confounding by indication might be responsible for
our findings. However, this analysis has several strengths that
distinguish it from previous observational reports on
outcome in this clinical arena. Merging data from DaVita
with data from the United States Renal Data System
(USRDS) allowed us to characterize and adjust for comor-
bidity and hospitalization at study entry and to update these
factors at cinacalcet initiation. Furthermore, use of USRDS
data allowed us to more fully identify mortality events.
Previous reports using only large dialysis chain data are
limited in this regard because of individual patients leaving a
particular provider or changing health insurance. Using
USRDS data, we identified approximately 3600 more deaths
than we would have identified using only DaVita-provided
mortality information. Our analysis mimicked an intent-to-
treat trial design by forcing patients who received cinacalcet
prescriptions to stay in the exposed arm. Any misclassifica-
tion bias that might have occurred with this approach would
serve only to minimize the likelihood of finding an
independent effect. Uniquely, compared with previous work,
our analyses included only patients who had received i.v.
vitamin D, the main treatment for SHPT, before cinacalcet
availability. Previous reports comparing outcomes among
exposed and unexposed patient populations have all been
susceptible to confounding by indication, in that patients
Table 4 | Continued
Parameter Parameter estimate s.e. Hazard ratio (95% CI) P
Bicarbonate, mEq/l (referent: X22–p30)
o22 0.043 0.041 1.04 (0.96–1.13) 0.2979
430 0.296 0.072 1.34 (1.17–1.55) o0.0001
Hemoglobin, g/dl (referent: X10–p12)
o10 0.177 0.139 1.19 (0.91–1.57) 0.2034
412 to p13 0.107 0.027 0.90 (0.85–0.95) o0.0001
413 0.079 0.029 0.92 (0.87–0.98) 0.0065
Kt/V UKM per treatment (referent: X1.2–p1.4)
o1.2 0.086 0.165 1.09 (0.79–1.51) 0.5997
41.4 0.231 0.039 0.79 (0.74–0.86) o0.0001
TSAT, % (referent: X20–o50)
o20 0.164 0.047 1.18 (1.07–1.29) 0.0005
X50 0.035 0.041 0.97 (0.89–1.05) 0.3941
Ferritin, ng/ml (referent: X200–o500)
o200 0.067 0.086 0.94 (0.79–1.11) 0.4303
X500 to o800 0.019 0.030 1.02 (0.96–1.08) 0.5205
X800 to o1000 0.006 0.039 1.01 (0.93–1.09) 0.8847
X1000 0.180 0.038 1.20 (1.11–1.29) o0.0001
WBC, mm3 (referent: X1000–p10,000)
o1000 3.105 0.705 22.31 (5.60–88.83) o0.0001
410,000 0.298 0.047 1.35 (1.23–1.48) o0.0001
Vascular access (referent: fistula)
Catheter 0.365 0.043 1.44 (1.32–1.57) o0.0001
Graft 0.188 0.032 1.21 (1.13–1.29) o0.0001
Other 0.932 0.648 2.54 (0.71–9.04) 0.1503
Abbreviations: BMI, body mass index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; CVD, cardiovascular disease; GI,
gastrointestinal; PTH, parathyroid hormone; s.e., standard error; TIA, transient ischemic attack; TSAT, transferrin saturation; UKM, urea kinetic modeling; WBC, white blood cell count.
aTime-dependent Cox proportional hazards regression model, adjusted for demographic characteristics, comorbidity, hospital days, vascular access, and laboratory
information.
bIncludes ill-defined complication of heart disease, tachycardia, palpitations, murmurs, acute pericarditis, acute and subacute endocarditis, other disease of pericardium, and
other diseases of the endocardium.
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Table 5 | Adjusted hazard ratios for cardiovascular mortalitya
Parameter Parameter estimate s.e. Hazard ratio (95% CI) P
Treatment (referent: non-cinacalcet patients) –0.281 0.0692 0.76 (0.66–0.86) o0.0001
Age, year (referent: 18–44)
45–64 0.520 0.119 1.68 (1.33–2.12) o0.0001
65–74 0.841 0.125 2.32 (1.81–2.96) o0.0001
X75 1.085 0.127 2.96 (2.31–3.80) o0.0001
Sex (referent: men) –0.084 0.047 0.92 (0.84–1.01) 0.0777
Race (referent: white)
African American –0.296 0.057 0.74 (0.67–0.83) o0.0001
Other –0.196 0.060 0.82 (0.73–0.92) 0.0010
Dialysis duration, year (referent: 1–3)
o1 –0.263 0.073 0.77 (0.67–0.89) 0.0003
3–5 0.123 0.063 1.13 (1.00–1.28) 0.0507
45 0.224 0.070 1.25 (1.09–1.43) 0.0013
BMI, kg/m2 (referent: X18–o25)
o18.5 0.483 0.088 1.62 (1.36–1.93) o0.0001
X25 to o30 –0.246 0.053 0.78 (0.70–0.87) o0.0001
X30 to o35 –0.389 0.071 0.68 (0.59–0.78) o0.0001
X35 to o40 –0.662 0.108 0.52 (0.42–0.64) o0.0001
X40 –0.623 0.130 0.54 (0.42–0.69) o0.0001
Primary cause of renal failure (referent: glomerulonephritis)
Diabetes 0.355 0.106 1.43 (1.16–1.75) 0.0008
Hypertension 0.249 0.098 1.28 (1.06–1.55) 0.0111
Other 0.179 0.108 1.20 (0.97–1.48) 0.0973
Hospital days (referent: 0)
1–3 0.006 0.074 1.01 (0.87–1.16) 0.9353
4–5 –0.030 0.095 0.97 (0.81–1.17) 0.7546
45 0.121 0.062 1.13 (1.00–1.28) 0.0510
Diabetes (referent: no) 0.144 0.069 1.15 (1.01–1.32) 0.0372
Congestive heart failure (referent: no) 0.318 0.051 1.37 (1.24–1.52) o0.0001
Atherosclerotic heart disease (referent: no) 0.088 0.052 1.09 (0.99–1.21) 0.0923
Peripheral vascular disease (referent: no) 0.157 0.048 1.17 (1.06–1.29) 0.0012
CVA/TIA (referent: no) 0.105 0.055 1.11 (1.00–1.24) 0.0583
Dysrhythmia (referent: no) 0.257 0.052 1.29 (1.17–1.43) o0.0001
Other CVDb (referent: no) 0.082 0.052 1.09 (0.98–1.20) 0.1194
Cancer (referent: no) –0.055 0.081 0.95 (0.81–1.11) 0.4995
GI bleeding (referent: no) 0.058 0.081 1.06 (0.91–1.24) 0.4692
COPD (referent: no) 0.168 0.056 1.18 (1.06–1.32) 0.0027
Liver disease (referent: no) –0.050 0.122 0.95 (0.75–1.21) 0.6806
Albumin, g/dl (referent: X4.0)
o3.6 0.850 0.049 2.34 (2.13–2.58) o0.0001
X3.6 to o4.0 0.340 0.043 1.41 (1.29–1.53) o0.0001
Corrected calcium, mg/dl (referent: X9.0–p10.2)
o9.0 –0.065 0.077 0.94 (0.81–1.09) 0.3998
410.2 0.161 0.059 1.17 (1.05–1.32) 0.0065
Phosphorus, mg/dl (referent: X3.5–o5.0)
o3.5 0.056 0.109 1.06 (0.85–1.31) 0.6045
X5.0 to o6.0 0.101 0.056 1.11 (0.99–1.24) 0.0711
X6.0 to o7.0 0.183 0.066 1.20 (1.05–1.37) 0.0056
X7.0 to o8.0 0.175 0.088 1.19 (1.00–1.42) 0.0467
X8.0 0.345 0.096 1.41 (1.17–1.70) 0.0003
Intact PTH, pg/ml (referent: 4150–p300)
o150 –0.022 0.070 0.98 (0.85–1.12) 0.7526
4300 to p600 0.053 0.056 1.06 (0.94–1.18) 0.3456
4600 0.256 0.079 1.29 (1.11–1.51) 0.0012
Table 5 Continued on the following page
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who never received the medication of interest were different
from those who did, in ways that cannot be adjusted for in
routine analyses. Because of previous observational reports of
survival benefit for patients exposed to i.v. vitamin D, we
believed that eliminating this feature as a potential con-
founder was important. Vitamin D use may have differed
modestly after exposure to cinacalcet; however, because this
event would be in the causal pathway of potential clinical
benefit, we did not find it reasonable to adjust for vitamin D
use in our model. In addition, we previously reported that
changes in vitamin D dose are very modest for patients in
this population with cinacalcet prescriptions.13 It is note-
worthy that we did not investigate potential mechanisms of
action as to the reason cinacalcet prescription was associated
with survival benefit, and any hypotheses in this regard must
be considered speculative.
In this prospectively designed observational cohort study,
we found that prescription of cinacalcet to hemodialysis
patients with SHPT, who have received i.v. vitamin D, was
associated with significant reductions in all-cause and
cardiovascular mortality. We must emphasize, however, that
these results are observational and cannot establish a cause-
and-effect relationship. These data do not definitively
establish a survival effect of cinacalcet, and we caution
against interpreting these data in any way other than
supporting the hypothesis that intervention with cinacalcet
and the resultant favorable effect on parameters of mineral
metabolism may be in the clinical pathway for cardiovascular
outcomes. Definitive evidence of actual clinical benefit will be
ascertained in the ongoing EVOLVE clinical trial. However,
our results provide compelling data, indicating that inter-
ventions to reduce calcium, phosphorus, and PTH levels are
associated with meaningful patient outcomes.
MATERIALS AND METHODS
Patients and data sources
Patient data from DaVita were obtained through a data-licensing
agreement. DaVita is a large dialysis provider in the United States,
serving approximately one-third of the US dialysis population. All
prevalent hemodialysis patients as of 1 August 2004 were selected,
and data were collected prospectively through 31 December 2006.
Using unique patient identifiers, data were linked to the Centers for
Medicare & Medicaid Services (CMS) end-stage renal disease
(ESRD) database by the USRDS through a data use agreement with
the National Institute of Diabetes and Digestive and Kidney
Diseases. Study approval was obtained from the Hennepin County
Medical Center Human Subjects Research Committee (Minneapolis,
Table 5 | Continued
Parameter Parameter estimate s.e. Hazard ratio (95% CI) P
Bicarbonate, mEq/l (referent: X22–p30)
o22 0.117 0.041 1.13 (1.04–1.22) 0.0042
430 0.180 0.101 1.20 (0.98–1.46) 0.0754
Hemoglobin, g/dl (referent: X10–p12)
o10 0.054 0.131 1.06 (0.82–1.36) 0.6809
412 to p13 –0.109 0.039 0.90 (0.83–0.97) 0.0047
413 –0.083 0.041 0.92 (0.85–1.00) 0.0443
Kt/V UKM per treatment (referent: X1.2–p1.4)
o1.2 0.011 0.140 1.01 (0.77–1.33) 0.9383
41.4 –0.239 0.053 0.79 (0.71–0.87) o0.0001
TSAT, % (referent: X20–o50)
o20 0.148 0.053 1.16 (1.05–1.28) 0.0051
X50 –0.166 0.062 0.85 (0.75–0.96) 0.0075
Ferritin, ng/ml (referent: X200–o500)
o200 –0.054 0.076 0.95 (0.82–1.10) 0.4760
X500 to o800 0.030 0.042 1.03 (0.95–1.12) 0.4691
X800 to o1000 –0.008 0.057 0.99 (0.89–1.11) 0.8861
X1000 0.101 0.055 1.11 (0.99–1.23) 0.0661
WBC, mm3 (referent: X1000–p10,000)
o1000 –5.181 0.525 0.01 (0.00–0.02) o0.0001
410,000 0.212 0.060 1.24 (1.10–1.39) 0.0004
Vascular access (referent: fistula)
Catheter 0.305 0.057 1.36 (1.21–1.52) o0.0001
Graft 0.228 0.047 1.26 (1.14–1.38) o0.0001
Other 0.796 0.524 2.22 (0.79–6.18) 0.1287
Abbreviations: BMI, body mass index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; CVD, cardiovascular disease;
GI, gastrointestinal; PTH, parathyroid hormone; s.e., standard error; TIA, transient ischemic attack; TSAT, transferrin saturation; UKM, urea kinetic modeling; WBC, white blood cell count.
aTime-dependent Cox proportional hazards regression model, adjusted for demographic characteristics, comorbidity, hospital days, vascular access, and laboratory information.
bIncludes ill-defined complication of heart disease, tachycardia, palpitations, murmurs, acute pericarditis, acute and subacute endocarditis, other disease of pericardium, and other
diseases of the endocardium.
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Minnesota, USA) and the Exempla Healthcare Institutional Review
Board (Denver, Colorado, USA).
The DaVita database provided information on demographics,
weight and height, laboratory values, dialysis treatment, vascular
access, i.v. vitamin D use, home medications, censoring (mortality,
outside transfer, modality change), and insurance coverage. The
CMS ESRD data provided information on ESRD initiation date,
comorbid conditions, ESRD cause, medical claims (which include
hospitalization information), and mortality date and cause.
Patient selection criteria
All hemodialysis patients as of August 2004 (n¼ 45,589) were eligible for
consideration for inclusion. Included patients were required to be aged
at least 18 years on 1 August 2004 and to have survived 90 days
(n¼ 43,848). To allow full identification of comorbidity and clinical
outcomes, included patients were required to have Medicare Centers for
Medicare & Medicaid Services, 7500 Security Blvd., Baltimore, MD
as primary payer and to have dialysis claims of X$675 in August,
September, and October 2004 (n¼ 29,202). Patients with cinacalcet
prescriptions before 31 October 2004 were excluded (remaining
n¼ 25,292) because of lack of adequate time to assess baseline
characteristics. Because this analysis was specifically designed to test
the a priori hypothesis that cinacalcet prescription independently
improved clinical outcomes, and because cinacalcet is specifically
indicated for patients with evidence of SHPT, all analyses were
restricted to patients with evidence of i.v. vitamin D use during the
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Figure 1 |Hazard ratios and 95% confidence intervals (CI) for mortality associated with cinacalcet prescription stratified by patient
characteristics. Each row reflects a multivariable adjusted model including the covariates in our final model (see Table 4). The number
of patients in each group (patients with and without cinacalcet prescriptions) within each stratum is represented by n. Circles represent
point estimates and horizontal lines 95% CI. The referent group for each analysis is the group without cinacalcet prescriptions. ASHD,
atherosclerotic heart disease; BMI, body mass index; CHF, congestive heart failure; CVA, cerebrovascular accident/transient ischemic attack;
DM, diabetes; GN, glomerulonephritis; HTN, hypertension; PTH, parathyroid hormone; PVD, peripheral vascular disease.
Kidney International (2010) 78, 578–589 587
GA Block et al.: Cinacalcet and survival in hemodialysis o r ig ina l a r t i c l e
baseline period, August through October 2004. A total of 1044 patients
(273 with cinacalcet prescriptions and 771 without) were censored due
to renal transplant, transferring out of DaVita, or loss to follow-up.
Applying these criteria left 19,186 patients in the cohort. Cinacalcet use
was defined as first cinacalcet prescription between 1 November 2004
and 31 December 2006. The final study population included 5976
cinacalcet patients and 13,210 non-cinacalcet patients.
Demographic information, comorbidity, hospitalization, and
vascular access
Demographic information was defined on 31 October 2004 for all
patients and included age, sex, race, dialysis duration, primary cause
of renal failure, and BMI. Comorbidity information was collected
from the medical evidence report (form CMS-2728) at dialysis
initiation. CMS claims data were used to collect additional
comorbidity information and hospital days before study start, from
1 May to 31 October 2004, for all patients. A standard methodology
was applied to collect this information.1 Comorbid conditions
included: diabetes, congestive heart failure, atherosclerotic heart
disease, peripheral vascular disease, cerebrovascular accident/tran-
sient ischemic attack, dysrhythmia, other cardiovascular diseases,
cancer, gastrointestinal bleeding, chronic obstructive pulmonary
disease, and liver disease. The most recent vascular access type
(catheter, graft, and arteriovenous fistula) in use before 1 November
2004 was characterized.
Laboratory data
Baseline laboratory data were determined from 1 August to 31 October
2004 and values closest to 31 October 2004 were used for all patients.
Laboratory values included albumin, corrected calcium, phosphorus,
PTH, bicarbonate, hemoglobin, Kt/V (dialysis adequacy: dialyzer
clearance multiplied by time divided by volume of water in patient’s
body), transferrin saturation, ferritin, and white blood cell count.
Home medication determinations
The DaVita home medication files contain detailed medication
information. Drug-specific files were created for cinacalcet by
searching for its generic and trade name. Each file was reviewed by
study personnel to verify the drug name, dose, and administration
frequency. Final drug-specific sequence files contained unique dates
for each prescription start, stop, and dosage change. Validity of
actual cinacalcet use was confirmed by biochemical evidence of
reductions in serum calcium, phosphorus, and PTH in the month
immediately following cinacalcet initiation.
The study cohort was examined for additional concomitant
medications often prescribed for hemodialysis patients (e.g., phosphate
binders). At least one record of medication prescription within the
medication class was required during the 3-month baseline period
(August–October 2004) to count as a medication exposure (Table 2).
Cinacalcet exposure
Cinacalcet exposure was defined as a dichotomous variable on the
basis of the presence (1, yes) or absence (0, no) of a cinacalcet
prescription during the study period, and was used as a time-
dependent variable on the basis of first cinacalcet prescription date.
Follow-up time for all patients started on 1 November 2004. Time
before first cinacalcet prescription was attributed to the non-
cinacalcet treatment group. Treatment status changed with first
cinacalcet prescription. Once designated as cinacalcet patients,
patients were considered to be cinacalcet patients until the end of
the study period.
Statistical methods
A time-dependent Cox proportional hazards regression model was
used to assess all-cause and cardiovascular mortality. Baseline
demographic, comorbidity, hospital days, vascular access, and
laboratory information, and phosphate binder and cardiovascular
medication use were used as covariates.
Cinacalcet prescription was treated as a time-dependent variable.
Age, dialysis duration, BMI, most recent vascular access type,
hospital days in the previous 6 months, and most recent laboratory
values within 3 months of cinacalcet start were updated on
cinacalcet initiation. Vascular access type and laboratory values
were also updated quarterly in the follow-up period for both patient
groups, except that calcium, phosphorus, and PTH were not
updated quarterly as these biochemical markers may be in the causal
pathway for any effect that cinacalcet may have on mortality.
Unadjusted and adjusted analyses were performed. Models for
adjusted analyses were adjusted for the factors noted above.
Homogeneity of treatment effect across levels of these factors was
assessed through additional models, including an interaction term
of treatment with one of the factors of interest (age, sex, race,
dialysis duration, diabetes, access type, BMI, phosphorus, and
PTH), and main effects of all variables. The final model included
significant (Po0.05) interaction terms and all main effects. As no
interactions were detected, no interaction terms were included in
the final model. Patients were followed from 1 November 2004 to
death. Censoring was applied for modality change (including kidney
transplant), withdrawal from dialysis, loss to follow-up (lack of CMS
ESRD dialysis claims), or end of 2006.
To address the possibility of lead-time bias that might be created
by difference in the dialysis duration between groups, a sensitivity
analysis was conducted. Groups based on dialysis duration (monthly
through month 120, yearly from months 121 to 168, and a single
cohort after month 168) were created. A propensity score was
developed to predict factors associated with cinacalcet prescription.
Factors important in this model included BMI, age, diabetes,
duration of SHPT, dialysis duration, sex, race, hospital days in the
preceding 6 months, albumin, calcium, phosphorus, and PTH. This
propensity score was divided by intervals that corresponded to
approximately 0.25 of an s.d. of the score. Cross-classifying the 24
propensity levels and the 126 dialysis duration categories yielded
2435 cohorts of cinacalcet and non-cinacalcet patients. Cinacalcet
patients were matched with non-cinacalcet patients by baseline
dialysis duration and propensity score. We subsequently performed
the same Cox regression model with Anderson–Gill approach
stratifying by matching groups.
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